Skip to main content

Advertisement

SpringerLink
Log in

Biomarkers of Renal Tumors: the Current State and Clinical Perspectives

  • Kidney Diseases (G Ciancio, Section Editor)
  • Published:
Current Urology Reports Aims and scope Submit manuscript

Abstract

Renal cell carcinoma (RCC) ranks the first death rate among the urogenital tumors, whereas its incidence follows the incidences of prostate and bladder cancer. The diagnosis of RCC at early stages allows immediately undertaking appropriate treatment, which significantly increases patients’ survival rate. Early and accurate diagnosis avoids inadequate treatment, provides the disease progression forecast, and permits to apply more efficient therapy. Unfortunately, the small renal tumors are usually asymptomatic resulting in the late diagnosis and, therefore, low efficacy of treatment. Thus, sensible and preventive biomarkers are essential for early RCC detection and monitoring of its progression. So far, many attempts were performed aimed at recognizing novel informative kidney tumor biomarkers applicable for early detection of the disease and possessing prognostic and predictive capabilities. This review summarizes recent advances in renal tumor biomarkers recognition, their diagnostic and prognostic values, and clinical feasibility.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Tumours of the Kidney. In: John, Guido, Jonathan, Isabell, editors. Tumors of the urinary system and male genital organs: IARC press; 2004.

  2. Novick AC. Kidney cancer: past, present, and future. Urol Oncol. 2007;25(3):188–95.

    Article  PubMed  Google Scholar 

  3. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015;65(1):5–29.

    Article  PubMed  Google Scholar 

  4. Martel CL, Lara PN. Renal cell carcinoma: current status and future directions. Crit Rev Oncol Hematol. 2003;45(2):177–90.

    Article  PubMed  Google Scholar 

  5. Powles T, Staehler M, Ljungberg B, Bensalah K, Canfield SE, Dabestani S, et al. European Association of Urology Guidelines for clear cell renal cancers that are resistant to vascular endothelial growth factor receptor-targeted therapy. Eur Urol. 2016.

  6. Gospodarowicz MK, Miller D, Groome PA, Greene FL, Logan PA, Sobin LH. The process for continuous improvement of the TNM classification. Cancer. 2004;100(1):1–5.

    Article  PubMed  Google Scholar 

  7. Xu J, Latif S, Wei S. Metastatic renal cell carcinoma presenting as gastric polyps: a case report and review of the literature. Int J Surg Case Rep. 2012;3(12):601–4.

    Article  PubMed  PubMed Central  Google Scholar 

  8. Li M, Rathmell K. The current status of biomarkers for renal cell carcinoma. ASCO Meeting Library. 2011;Educational Book 2011:153–7.

  9. •• Golovastova MO, Tsoy LV, Bocharnikova AV, Korolev DO, Gancharova OS, Alekseeva EA, et al. The cancer-retina antigen recoverin as a potential biomarker for renal tumors. Tumour Biol. 2016;37(7):9899–907. This is the first report on the cancer-retina antigen as a biomarker for renal tumors.

    Article  CAS  PubMed  Google Scholar 

  10. Morrissey JJ, London AN, Luo J, Kharasch ED. Urinary biomarkers for the early diagnosis of kidney cancer. Mayo Clin Proc. 2010;85(5):413–21.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Skates S, Iliopoulos O. Molecular markers for early detection of renal carcinoma: investigative approach. Clin Cancer Res. 2004;10(18 Pt 2):6296S–301S.

    Article  CAS  PubMed  Google Scholar 

  12. Gupta V, Bamezai RN. Human pyruvate kinase M2: a multifunctional protein. Protein Sci. 2010;19(11):2031–44.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Roigas J, Schulze G, Raytarowski S, Jung K, Schnorr D, Loening SA. Tumor M2 pyruvate kinase in plasma of patients with urological tumors. Tumour Biol. 2001;22(5):282–5.

    Article  CAS  PubMed  Google Scholar 

  14. Weinberger R, Appel B, Stein A, Metz Y, Neheman A, Barak M. The pyruvate kinase isoenzyme M2 (Tu M2-PK) as a tumour marker for renal cell carcinoma. Eur J Cancer Care. 2007;16(4):333–7.

    Article  CAS  Google Scholar 

  15. Wechsel HW, Petri E, Bichler KH, Feil G. Marker for renal cell carcinoma (RCC): the dimeric form of pyruvate kinase type M2 (Tu M2-PK). Anticancer Res. 1999;19(4A):2583–90.

    CAS  PubMed  Google Scholar 

  16. Rioux-Leclercq N, Fergelot P, Zerrouki S, Leray E, Jouan F, Bellaud P, et al. Plasma level and tissue expression of vascular endothelial growth factor in renal cell carcinoma: a prospective study of 50 cases. Hum Pathol. 2007;38(10):1489–95.

    Article  CAS  PubMed  Google Scholar 

  17. Fujita N, Okegawa T, Tambo M, Shishido T, Nutahara K, Higashihara E. Predicting postoperative recurrence of renal cell carcinoma using serum vascular endothelial growth factor. Nihon Hinyokika Gakkai zasshi The Japanese Journal of Urology. 2013;104(1):1–5.

    CAS  PubMed  Google Scholar 

  18. Negrier S, Chabaud S, Escudier B, Ravaud A, Chevreau C, Blay JY, et al. Serum level of vascular endothelial growth factor (VEGF) as an independent prognostic factor in metastatic renal cell carcinoma (MRCC). J Clin Oncol. 2007;25(18S):5044.

    Google Scholar 

  19. Werther K, Christensen IJ, Nielsen HJ. Determination of vascular endothelial growth factor (VEGF) in circulating blood: significance of VEGF in various leucocytes and platelets. Scand J Clin Lab Invest. 2002;62(5):343–50.

    Article  CAS  PubMed  Google Scholar 

  20. Paju A, Jacobsen J, Rasmuson T, Stenman UH, Ljungberg B. Tumor associated trypsin inhibitor as a prognostic factor in renal cell carcinoma. J Urol. 2001;165(3):959–62.

    Article  CAS  PubMed  Google Scholar 

  21. Lukkonen A, Lintula S, von Boguslawski K, Carpen O, Ljungberg B, Landberg G, et al. Tumor-associated trypsin inhibitor in normal and malignant renal tissue and in serum of renal-cell carcinoma patients. Int J Cancer. 1999;83(4):486–90.

    Article  CAS  PubMed  Google Scholar 

  22. McKiernan JM, Buttyan R, Bander NH, de la Taille A, Stifelman MD, Emanuel ER, et al. The detection of renal carcinoma cells in the peripheral blood with an enhanced reverse transcriptase-polymerase chain reaction assay for MN/CA9. Cancer. 1999;86(3):492–7.

    Article  CAS  PubMed  Google Scholar 

  23. Meria P, Toubert ME, Cussenot O, Bassi S, Janssen T, Desgrandchamps F, et al. Tumour-associated trypsin inhibitor and renal cell carcinoma. Eur Urol. 1995;27(3):223–6.

    CAS  PubMed  Google Scholar 

  24. Yildiz I, Sen F, Kilic L, Keskin S, Duranyildiz D, Bilgin E, et al. Serum M65 as a biomarker for metastatic renal cell carcinoma. Clin Genitourin Cancer. 2013;11(3):290–6.

    Article  PubMed  Google Scholar 

  25. Tretiakova MS, Sahoo S, Takahashi M, Turkyilmaz M, Vogelzang NJ, Lin F, et al. Expression of alpha-methylacyl-CoA racemase in papillary renal cell carcinoma. Am J Surg Pathol. 2004;28(1):69–76.

    Article  PubMed  Google Scholar 

  26. Ozcan A, Zhai J, Hamilton C, Shen SS, Ro JY, Krishnan B, et al. PAX-2 in the diagnosis of primary renal tumors: immunohistochemical comparison with renal cell carcinoma marker antigen and kidney-specific cadherin. Am J Clin Pathol. 2009;131(3):393–404.

    Article  CAS  PubMed  Google Scholar 

  27. Zhang W, Wang K, Yu W, Liu Y, Chu J, Jiang Y, et al. Diagnostic utility of S100A1, GLUT-1 and Caveolin-1 in renal tumors with oncocytic features: a comparative study. Zhonghua bing li xue za zhi = Chin J Pathol. 2015;44(11):767–71.

    CAS  Google Scholar 

  28. Skinnider BF, Folpe AL, Hennigar RA, Lim SD, Cohen C, Tamboli P, et al. Distribution of cytokeratins and vimentin in adult renal neoplasms and normal renal tissue: potential utility of a cytokeratin antibody panel in the differential diagnosis of renal tumors. Am J Surg Pathol. 2005;29(6):747–54.

    Article  PubMed  Google Scholar 

  29. Avery AK, Beckstead J, Renshaw AA, Corless CL. Use of antibodies to RCC and CD10 in the differential diagnosis of renal neoplasms. Am J Surg Pathol. 2000;24(2):203–10.

    Article  CAS  PubMed  Google Scholar 

  30. Martignoni G, Pea M, Chilosi M, Brunelli M, Scarpa A, Colato C, et al. Parvalbumin is constantly expressed in chromophobe renal carcinoma. Modern Pathol. 2001;14(8):760–7.

    Article  CAS  Google Scholar 

  31. Rocca PC, Brunelli M, Gobbo S, Eccher A, Bragantini E, Mina MM, et al. Diagnostic utility of S100A1 expression in renal cell neoplasms: an immunohistochemical and quantitative RT-PCR study. Modern Pathol. 2007;20(7):722–8.

    Article  CAS  Google Scholar 

  32. Memeo L, Jhang J, Assaad AM, McKiernan JM, Murty VV, Hibshoosh H, et al. Immunohistochemical analysis for cytokeratin 7, KIT, and PAX2: value in the differential diagnosis of chromophobe cell carcinoma. Am J Clin Pathol. 2007;127(2):225–9.

    Article  PubMed  Google Scholar 

  33. Gupta R, Balzer B, Picken M, Osunkoya AO, Shet T, Alsabeh R, et al. Diagnostic implications of transcription factor Pax 2 protein and transmembrane enzyme complex carbonic anhydrase IX immunoreactivity in adult renal epithelial neoplasms. Am J Surg Pathol. 2009;33(2):241–7.

    Article  PubMed  Google Scholar 

  34. • Tan PH, Cheng L, Rioux-Leclercq N, Merino MJ, Netto G, Reuter VE, et al. Renal tumors: diagnostic and prognostic biomarkers. Am J Surg Pathol. 2013;37(10):1518–31. This article summarizes the data available on biomarkers useful in differential diagnosis of different subtypes of renal tumors, and on prognostic biomarkers and their correlation with clinicopathological parameters.

    Article  PubMed  PubMed Central  Google Scholar 

  35. Tumours of the Kidney. In: Eble, Sauter, Epstein, Sesterhenn, editors. Pathology and genetics of tumours of the urinary system and male genital organs: IARC Press; 2004.

  36. Bonsib SM, Bhalodia A. Renal neoplasms: an update on immunohistochemical and histochemical features. Connection. 2010:178–86.

  37. Khor LY, Tan PH. Diagnostic biomarkers in eosinophilic renal neoplasms. Urol Clin N Am. 2016;43(1):87–94.

    Article  Google Scholar 

  38. Luders C, Kristiansen G. Oncocytoma versus chromophobe renal cell carcinoma: is there something in between? Pathologe. 2016;37(2):153–8.

    Article  CAS  PubMed  Google Scholar 

  39. Decastro GJ, McKiernan JM. Epidemiology, clinical staging, and presentation of renal cell carcinoma. Urol Clin N Am. 2008;35(4):581–92. vi.

    Article  Google Scholar 

  40. Muglia VF, Prando A. Renal cell carcinoma: histological classification and correlation with imaging findings. Radiol Bras. 2015;48(3):166–74.

    Article  PubMed  PubMed Central  Google Scholar 

  41. Thoenes W, Storkel S, Rumpelt HJ. Human chromophobe cell renal carcinoma. Virchows Arch B Cell Pathol Incl Mol Pathol. 1985;48(3):207–17.

    Article  CAS  PubMed  Google Scholar 

  42. Biswas B, Wahal SP, Gulati A. Renal oncocytoma: a diagnostic dilemma on cytology. J Cytol Indian Acad Cytol. 2014;31(1):59–60.

    Article  Google Scholar 

  43. Huang W, Kanehira K, Drew S, Pier T. Oncocytoma Can be differentiated from its renal cell carcinoma mimics by a panel of markers an automated tissue microarray study. Appl Immunohisto M M. 2009;17(1):12–7.

    Article  CAS  Google Scholar 

  44. Choi YD, Kim KS, Ryu S, Park Y, Cho NH, Rha SH, et al. Claudin-7 is highly expressed in chromophobe renal cell carcinoma and renal oncocytoma. J Korean Med Sci. 2007;22(2):305–10.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  45. Youssef YM, White NM, Grigull J, Krizova A, Samy C, Mejia-Guerrero S, et al. Accurate molecular classification of kidney cancer subtypes using microRNA signature. Eur Urol. 2011;59(5):721–30.

    Article  CAS  PubMed  Google Scholar 

  46. Gobe G, Rubin M, Williams G, Sawczuk I, Buttyan R. Apoptosis and expression of Bcl-2, Bcl-XL, and Bax in renal cell carcinomas. Cancer Investig. 2002;20(3):324–32.

    Article  CAS  Google Scholar 

  47. Saker Z, Tsintsadze O, Jiqia I, Managadze L, Chkhotua A. Importance of apoptosis markers (MDM2, BCL-2 and Bax) in conventional renal cell carcinoma. Georgian Med News. 2015;249:27–33.

    Google Scholar 

  48. Vasavada SP, Novick AC, Williams BR. P53, bcl-2, and Bax expression in renal cell carcinoma. Urology. 1998;51(6):1057–61.

    Article  CAS  PubMed  Google Scholar 

  49. Itoi T, Yamana K, Bilim V, Takahashi K, Tomita F. Impact of frequent Bcl-2 expression on better prognosis in renal cell carcinoma patients. Br J Cancer. 2004;90(1):200–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  50. Virman JP, Bono P, Luukkaala TH, Sunela KL, Kujala PM, Kellokumpu-Lehtinen PL. Combined angiogenesis and proliferation markers’ expressions as long-term prognostic factors in renal cell cancer. Clin Genitourin Cancer. 2016;14(4):e283–9.

    Article  PubMed  Google Scholar 

  51. Zerati M, Leite KR, Pontes-Junior J, Segre CC, Reis ST, Srougi M, et al. Carbonic Anhydrase IX is not a predictor of outcomes in non-metastatic clear cell renal cell carcinoma—a digital analysis of tissue microarray. Int Braz J Urol. 2013;39(4):484–92.

    Article  PubMed  Google Scholar 

  52. Soyupak B, Erdogan S, Ergin M, Seydaoglu G, Kuzgunbay B, Tansug Z. CA9 expression as a prognostic factor in renal clear cell carcinoma. Urol Int. 2005;74(1):68–73.

    Article  CAS  PubMed  Google Scholar 

  53. Bui MHT, Visapaa H, Seligson D, Kim H, Han KR, Huang Y, et al. Prognostic value of carbonic anhydrase IX and Ki67 as predictors of survival for renal clear cell carcinoma. J Urol. 2004;171(6):2461–6.

    Article  PubMed  Google Scholar 

  54. Xie H, Zhu Y, An H, Wang H, Zhu Y, Fu H, et al. Increased B4GALT1 expression associates with adverse outcome in patients with non-metastatic clear cell renal cell carcinoma. Oncotarget. 2016.

  55. Gayed BA, Youssef RF, Bagrodia A, Darwish OM, Kapur P, Sagalowsky A, et al. Ki67 is an independent predictor of oncological outcomes in patients with localized clear-cell renal cell carcinoma. BJU Int. 2014;113(4):668–73.

    Article  PubMed  Google Scholar 

  56. Dudderidge TJ, Stoeber K, Loddo M, Atkinson G, Fanshawe T, Griffiths DF, et al. Mcm2, Geminin, and KI67 define proliferative state and are prognostic markers in renal cell carcinoma. Clin Cancer Res. 2005;11(7):2510–7.

    Article  CAS  PubMed  Google Scholar 

  57. Li G, Forest F, Feng G, Gentil-Perret A, Peoc’h M, Cottier M, et al. A novel marker ADAM17 for clear cell renal cell carcinomas: implication for patients’ prognosis. Urol Oncol. 2014;32(8):1272–6.

    Article  CAS  PubMed  Google Scholar 

  58. Shi ZG, Li SQ, Li ZJ, Zhu XJ, Xu P, Liu G. Expression of vimentin and survivin in clear cell renal cell carcinoma and correlation with p53. Clin Transl Oncol. 2015;17(1):65–73.

    Article  CAS  PubMed  Google Scholar 

  59. Kruck S, Merseburger AS, Hennenlotter J, Scharpf M, Eyrich C, Amend B, et al. High cytoplasmic expression of p27(Kip1) is associated with a worse cancer-specific survival in clear cell renal cell carcinoma. BJU Int. 2012;109(10):1565–70.

    Article  PubMed  Google Scholar 

  60. Zamparese R, Pannone G, Santoro A, Lo Muzio L, Corsi F, Pedicillo MC, et al. Survivin expression in renal cell carcinoma. Cancer Investig. 2008;26(9):929–35.

    Article  CAS  Google Scholar 

  61. Xiong C, Liu H, Chen Z, Yu Y, Liang C. Prognostic role of survivin in renal cell carcinoma: a system review and meta-analysis. Eur J Int Med. 2016;33:102–7.

    Article  CAS  Google Scholar 

  62. Yoo SH, Lee K, Chae JY, Moon KC. CD151 expression can predict cancer progression in clear cell renal cell carcinoma. Histopathology. 2011;58(2):191–7.

    Article  PubMed  Google Scholar 

  63. Kwon HJ, Min SY, Park MJ, Lee C, Park JH, Chae JY, et al. Expression of CD9 and CD82 in clear cell renal cell carcinoma and its clinical significance. Pathol Res Pract. 2014;210(5):285–90.

    Article  CAS  PubMed  Google Scholar 

  64. Sandlund J, Hedberg Y, Bergh A, Grankvist K, Ljungberg B, Rasmuson T. Endoglin (CD105) expression in human renal cell carcinoma. BJU Int. 2006;97(4):706–10.

    Article  CAS  PubMed  Google Scholar 

  65. Girgis H, Masui O, White NM, Scorilas A, Rotondo F, Seivwright A, et al. Lactate dehydrogenase A is a potential prognostic marker in clear cell renal cell carcinoma. Mol Cancer. 2014;13:101.

    Article  PubMed  PubMed Central  Google Scholar 

  66. Song J, Chen X, Bai J, Liu Q, Li H, Xie J, et al. Discoidin domain receptor 1 (DDR1), a promising biomarker, induces epithelial to mesenchymal transition in renal cancer cells. Tumour Biol. 2016;37(8):11509–21.

    Article  CAS  PubMed  Google Scholar 

  67. Mo R, Peng J, Xiao J, Ma J, Li W, Wang J, et al. High TXNDC5 expression predicts poor prognosis in renal cell carcinoma. Tumour Biol. 2016;37(7):9797–806.

    Article  CAS  PubMed  Google Scholar 

  68. Vtorushin SV, Tarakanova VO, Zavyalova MV. Molecular biological predictors for kidney cancer. Arkh Patol. 2016;78(1):56–61.

    Article  CAS  PubMed  Google Scholar 

  69. Zhang Z, Li J, Zheng H, Yu C, Chen J, Liu Z, et al. Expression and cytoplasmic localization of SAM68 is a significant and independent prognostic marker for renal cell carcinoma. Cancer Epidemiol Biomark Prev. 2009;18(10):2685–93.

    Article  CAS  Google Scholar 

  70. Zhao Z, Lu J, Han L, Wang X, Man Q, Liu S. Prognostic significance of two lipid metabolism enzymes, HADHA and ACAT2, in clear cell renal cell carcinoma. Tumour Biol. 2016;37(6):8121–30.

    Article  CAS  PubMed  Google Scholar 

  71. • Gabril M, Girgis H, Scorilas A, Rotondo F, Wala S, Bjarnason GA, et al. S100A11 is a potential prognostic marker for clear cell renal cell carcinoma. Clin Exp Metastasis. 2016;33(1):63–71. This article contains a comprehensive data on the expression of the S100A11 protein and its correlation with clinicopathologic parameters and survival rate within a large cohort of patients with clear cell renal cell carcinoma.

    Article  CAS  PubMed  Google Scholar 

  72. Virman J, Soini Y, Kujala P, Luukkaala T, Salminen T, Sunela K, et al. Claudins as prognostic factors for renal cell cancer. Anticancer Res. 2014;34(8):4181–7.

    PubMed  Google Scholar 

  73. Men W, Martin TA, Ruge F, Zhang N, Du P, Yang Y, et al. Expression of claudins in human clear cell renal cell carcinoma. Cancer Genomics Proteomics. 2015;12(1):1–8.

    PubMed  Google Scholar 

  74. Shin Lee J, Seok Kim H, Bok Kim Y, Cheol Lee M, Soo PC. Expression of PTEN in renal cell carcinoma and its relation to tumor behavior and growth. J Surg Oncol. 2003;84(3):166–72.

    Article  PubMed  Google Scholar 

  75. Rioux-Leclercq N, Turlin B, Bansard J, Patard J, Manunta A, Moulinoux JP, et al. Value of immunohistochemical Ki-67 and p53 determinations as predictive factors of outcome in renal cell carcinoma. Urology. 2000;55(4):501–5.

    Article  CAS  PubMed  Google Scholar 

  76. Aaltomaa S, Lipponen P, Ala-Opas M, Eskelinen M, Syrjanen K. Prognostic value of Ki-67 expression in renal cell carcinomas. Eur Urol. 1997;31(3):350–5.

    CAS  PubMed  Google Scholar 

  77. Slaby O, Jancovicova J, Lakomy R, Svoboda M, Poprach A, Fabian P, et al. Expression of miRNA-106b in conventional renal cell carcinoma is a potential marker for prediction of early metastasis after nephrectomy. J Exp Clin Cancer Research CR. 2010;29:90.

    Article  PubMed  Google Scholar 

  78. Bukowski RM. Cytokine therapy for metastatic renal cell carcinoma. Semin Urol Oncol. 2001;19(2):148–54.

    CAS  PubMed  Google Scholar 

  79. • Hutson TE. Targeted therapies for the treatment of metastatic renal cell carcinoma: clinical evidence. The oncologist. 2011;16 Suppl 2:14–22. This article reports the clinical evidence supporting the benefits of targeted agents in the treatment of patients with metastatic renal cell carcinoma.

    Article  PubMed  PubMed Central  Google Scholar 

  80. Linehan WM, Srinivasan R. Targeted therapies: treating advanced kidney cancer-miles to go before we sleep. Nat Rev Clin Oncol. 2013;10(11):614–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  81. Hutson TE. Targeted therapy for renal cell carcinoma: a new treatment paradigm. Proc Natl Acad Sci U S A. 2007;20(3):244–8.

    Google Scholar 

  82. Choueiri TK, Cheng S, Qu AQ, Pastorek J, Atkins MB, Signoretti S. Carbonic anhydrase IX as a potential biomarker of efficacy in metastatic clear-cell renal cell carcinoma patients receiving sorafenib or placebo: analysis from the treatment approaches in renal cancer global evaluation trial (TARGET). Urol Oncol. 2013;31(8):1788–93.

    Article  CAS  PubMed  Google Scholar 

  83. Ferguson T, Gore M. Which patients with renal cancer may benefit from sunitinib therapy? Ther Adv Med Oncol. 2010;2(2):69–74.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  84. Ma X, Wang L, Li H, Zhang Y, Gao Y, Guo G, et al. Predictive immunohistochemical markers related to drug selection for patients treated with sunitinib or sorafenib for metastatic renal cell cancer. Sci Rep. 2016;6:30886.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  85. Garcia-Roig M, Ortiz N, Lokeshwar V. Molecular marker for predicting treatment response in advanced renal cell carcinoma: does the promise fulfill clinical need? Curr Urol Rep. 2014;15(1):375.

    Article  PubMed  PubMed Central  Google Scholar 

  86. Pick AM, Cochrane ZR. Identification of biomarkers in pazopanib treated patients with renal cell carcinoma. Transl Androl Urol. 2013;2(2):117–8.

    PubMed  PubMed Central  Google Scholar 

  87. Hutson TE, Davis ID, Macheils JH, de Souza PL, Baker K, Bordogna W. Biomarker analysis and final efficacy and safety results of a phase II renal cell carcinoma trial with pazopanib. J Clin Oncol. 2008;26:5046.

    CAS  Google Scholar 

  88. Li S, Kong Y, Si L, Chi Z, Cui C, Sheng X, et al. Phosphorylation of mTOR and S6RP predicts the efficacy of everolimus in patients with metastatic renal cell carcinoma. BMC Cancer. 2014;14:376.

    Article  PubMed  PubMed Central  Google Scholar 

  89. Cho D, Signoretti S, Dabora S, Regan M, Seeley A, Mariotti M, et al. Potential histologic and molecular predictors of response to temsirolimus in patients with advanced renal cell carcinoma. Clin Genitourin Cancer. 2007;5(6):379–85.

    Article  CAS  PubMed  Google Scholar 

  90. Armstrong AJ, George DJ, Halabi S. Serum lactate dehydrogenase predicts for overall survival benefit in patients with metastatic renal cell carcinoma treated with inhibition of mammalian target of rapamycin. J Clin Oncol. 2012;30(27):3402–7.

    Article  CAS  PubMed  Google Scholar 

  91. Caserta S, Borger JG, Zamoyska R. Central and effector memory CD4 and CD8 T-cell responses to tumor-associated antigens. Crit Rev Immunol. 2012;32(2):97–126.

    Article  CAS  PubMed  Google Scholar 

  92. Savvateeva LV, Schwartz AM, Gorshkova LB, Gorokhovets NV, Makarov VA, Reddy VP, et al. Prophylactic admission of an in vitro reconstructed complexes of human recombinant heat shock proteins and melanoma antigenic peptides activates anti-melanoma responses in mice. Curr Mol Med. 2015;15(5):462–8.

    Article  CAS  PubMed  Google Scholar 

  93. Ho TW, McKhann GM, Griffin JW. Human autoimmune neuropathies. Annu Rev Neurosci. 1998;21:187–226.

    Article  CAS  PubMed  Google Scholar 

  94. Adamus G. Autoantibody targets and their cancer relationship in the pathogenicity of paraneoplastic retinopathy. Autoimmun Rev. 2009;8(5):410–4.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  95. Lu Y, He S, Jia L, Khan NW, Heckenlively JR. Two mouse models for recoverin-associated autoimmune retinopathy. Mol Vis. 2010;16:1936–48.

    CAS  PubMed  PubMed Central  Google Scholar 

  96. Matus G, Dicato M, Focan C. Cancer associated retinopathy (CAR). Two clinical cases and review of the literature. Rev Med Liege. 2007;62(3):166–9.

    CAS  PubMed  Google Scholar 

  97. Maeda A, Ohguro H, Maeda T, Wada I, Sato N, Kuroki Y, et al. Aberrant expression of photoreceptor-specific calcium-binding protein (recoverin) in cancer cell lines. Cancer Res. 2000;60(7):1914–20.

    CAS  PubMed  Google Scholar 

  98. Ohguro H, Odagiri H, Miyagawa Y, Ohguro I, Sasaki M, Nakazawa M. Clinicopathological features of gastric cancer cases and aberrantly expressed recoverin. Tohoku J Exp Med. 2004;202(3):213–9.

    Article  PubMed  Google Scholar 

  99. Matsuo S, Ohguro H, Ohguro I, Nakazawa M. Clinicopathological roles of aberrantly expressed recoverin in malignant tumor cells. Ophthalmic Res. 2010;43(3):139–44.

    Article  CAS  PubMed  Google Scholar 

  100. Bazhin AV, De Smet C, Golovastova MO, Schmidt J, Philippov PP. Aberrant demethylation of the recoverin gene is involved in the aberrant expression of recoverin in cancer cells. Exp Dermatol. 2010;19(11):1023–5.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

This work was supported in part by grants nos. 15-04-05171 and 16-54-53115 from the Russian Foundation for Basic Research and by grant no. 8151101119 from the National Natural Science Foundation of China.

Author information

Authors and Affiliations

  1. Department of Cell Signaling, Belozersky Institute of Physico-Chemical Biology, Lomonosov Moscow State University, 119991, Moscow, Russia

    Marina O. Golovastova, Evgeni Yu. Zernii, Pavel P. Philippov & Andrey A. Zamyatnin Jr.

  2. Institute of Uronephrology and Human Reproductive Health, Sechenov First Moscow State Medical University, 119991, Moscow, Russia

    Dmitry O. Korolev & Andrey Z. Vinarov

  3. Anatomic Pathology Department, Sechenov First Moscow State Medical University, 119991, Moscow, Russia

    Larisa V. Tsoy & Vladimir A. Varshavsky

  4. Department of Urology, The Fourth Hospital of Harbin Medical University, Harbin, China

    Wan-Hai Xu

  5. Institute of Molecular Medicine, Sechenov First Moscow State Medical University, 119991, Moscow, Russia

    Andrey A. Zamyatnin Jr.

Authors
  1. Marina O. Golovastova
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Dmitry O. Korolev
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Larisa V. Tsoy
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Vladimir A. Varshavsky
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Wan-Hai Xu
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Andrey Z. Vinarov
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Evgeni Yu. Zernii
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Pavel P. Philippov
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Andrey A. Zamyatnin Jr.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Andrey A. Zamyatnin Jr..

Ethics declarations

Conflict of Interest

Marina O. Golovastova, Dmitry O. Korolev, Larisa V. Tsoy, Vladimir A. Varshavsky, Andrey Z. Vinarov, and Evgeni Yu. Zernii each declare no potential conflicts of interest.

Wan-Hai Xu reports a grant from the National Natural Science Foundation of China.

Pavel P. Philippov and Andrey A. Zamyatnin Jr. each report a grant from the Russian Foundation for Basic Research.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

This article is part of the Topical Collection on Kidney Diseases

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Golovastova, M.O., Korolev, D.O., Tsoy, L.V. et al. Biomarkers of Renal Tumors: the Current State and Clinical Perspectives. Curr Urol Rep 18, 3 (2017). https://doi.org/10.1007/s11934-017-0655-1

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11934-017-0655-1

Keywords

Search

Navigation